

# Diagnosis of cancer in Nairobi, Kenya: duration and causes of delay

<b>Submission date</b> 24/03/2025	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 17/04/2025	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 20/02/2026	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Cancer is a leading cause of death worldwide. Patients with cancer in sub-Saharan Africa have a higher death rate than patients with cancer in high-income countries. This is largely because the majority of patients in sub-Saharan Africa present with cancer late, when it has done a lot of damage to the body and the chances of a cure are low. It is therefore important that patients are diagnosed earlier so that they can receive treatment before the cancer spreads. This study aims to better understand delays in the pathway to care and the factors contributing to these delays in Kenya. The study is focused on four common cancer types: breast, colorectal, head-and-neck, and cervical cancer. These cancers are treatable if diagnosed early and often present noticeable symptoms.

### Who can participate?

Patients aged 18 years and older who have been diagnosed for the first time with breast, colorectal, head-and-neck, or cervical cancer, who present at the Kenyatta National Hospital, a government-owned national referral and specialized hospital in Kenya.

### What does the study involve?

The study will involve one-to-one interviews with patients diagnosed with the selected cancers. A semi-structured questionnaire will be used to explore the time to diagnosis in three stages: The first stage is from when the patient first notices a change in their body/symptom to when they first present to a formal healthcare provider.

The second stage is from when the patient presents to a formal healthcare provider to when they receive a cancer diagnosis.

The third stage is from when the patient receives a diagnosis to when they start treatment.

The study will recruit 40 to 50 patients for each cancer type from Kenyatta National Hospital. A clinician or nurse from the hospital will assist in identifying and approaching the eligible patients. If the patient agrees to participate, their contact details will be shared with the research team, who will then arrange an interview.

All participants will be required to provide written consent before the interviews.

The researchers will examine the information from the interviews to calculate the time between each of the stages and identify the reasons for the delay at each stage.

What are the possible benefits and risks of participating?

There are no direct benefits or risks of participating in the study. However, some patients may find it distressing to discuss their cancer journey. The research team is trained to provide support and refer patients to emotional support services if needed. If a patient becomes too distressed, the interview will be stopped.

Where is the study run from?

The study is a collaboration between the African Population and Health Research Center (APHRC) in Kenya, the University of Birmingham in the UK, and the University of Ibadan in Nigeria.

When is the study starting and how long is it expected to run for?

November 2024 to July 2025

Who is funding the study?

National Institute for Health and Care Research (NIHR) Global Health Programme (UK)

Who is the main contact?

Lyagamula Kisia, lkisia@aphrc.org

## Contact information

### Type(s)

Principal investigator

### Contact name

Prof Richard Lilford

### ORCID ID

<https://orcid.org/0000-0002-0634-984X>

### Contact details

University of Birmingham

Edgbaston

Birmingham

United Kingdom

B15 2TT

+44 (0)121 414 6772

[r.j.lilford@bham.ac.uk](mailto:r.j.lilford@bham.ac.uk)

### Type(s)

Public, Scientific

### Contact name

Dr Lyagamula Kisia

### ORCID ID

<https://orcid.org/0000-0002-2045-6158>

### Contact details

APHRC Campus  
Manga Cl  
Nairobi  
Kenya  
PO Box 10787-00100  
+254 (0)720 098388  
lkisia@aphrc.org

## Additional identifiers

National Institute for Health and Care Research (NIHR)  
158242

## Study information

### Scientific Title

The delays in cancer care and the associated causes of the delays in Nairobi, Kenya

### Study objectives

The findings will provide preliminary evidence to inform policy and decision-makers in designing and implementing multilevel and holistic approaches to cancer control and improving the overall care pathway. It will also inform subsequent work packages in a programme of work in which this is the first part.

### Ethics approval required

Ethics approval required

### Ethics approval(s)

1. approved 05/11/2024, African Population Health Research Center (APHRC) (APHRC Campus, Manga Close, Kirawa road, Nairobi, PO Box 10787-00100, Kenya; +254 (0)722205933; info@aphrc.org), ref: DOR/2024/058
2. submitted 15/11/2024, Kenyatta National Hospital/University of Nairobi (Ethics and Research Committee, College of Health Sciences, Nairobi, PO Box 19676-00202, Kenya; +254 (0) 721257746; uoknh\_erc@uonbi.ac.ke), ref: N/A
3. notYetSubmitted

### Study design

Mixed-methods cross sectional study

### Primary study design

Observational

### Study type(s)

Other

### Health condition(s) or problem(s) studied

Breast, colorectal, head-and-neck, or cervical cancer

## **Interventions**

Semi-structured interviews with patients with a recent diagnosis of cancer to elicit patients' accounts of their cancer care pathway

The study will involve one-to-one interviews with patients diagnosed with the selected cancers. A semi-structured questionnaire will be used to explore the time to diagnosis in three stages: The first stage is from when the patient first notices a change in their body/symptom to when they first present to a formal healthcare provider.

The second stage is from when the patient presents to a formal healthcare provider to when they receive a cancer diagnosis.

The third stage is from when the patient receives a diagnosis to when they start treatment.

The study will recruit 40 to 50 patients for each cancer type from Kenyatta National Hospital. A clinician or nurse from the hospital will assist in identifying and approaching the eligible patients. If the patient agrees to participate, their contact details will be shared with the research team, who will then arrange an interview.

All participants will be required to provide written consent before the interviews.

The researchers will examine the information from the interviews to calculate the time between each of the stages and identify the reasons for the delay at each stage.

## **Intervention Type**

Other

## **Primary outcome(s)**

1. Duration of delays will be measured using a semi-structured interview instrument at three timepoints that is point 1 (recognition of symptoms to presentation to a formal healthcare provider), point 2 (presentation to a formal healthcare provider to diagnosis), point 3 (diagnosis to resolution).

2. Patient experiences will be elicited using a semi-structured interview instrument at three timepoints that is point 1 (recognition of symptoms to presentation to a formal healthcare provider), point 2 (presentation to a formal healthcare provider to diagnosis), point 3 (diagnosis to resolution).

## **Key secondary outcome(s)**

There are no secondary outcome measures

## **Completion date**

31/07/2025

## **Eligibility**

### **Key inclusion criteria**

1. Patients with a first histologically confirmed diagnosis of breast, colorectal, head and neck, or cervical cancer
2. Patients aged 18 years and above
3. Patients referred from the Nairobi Metropolitan Area (NMA)
4. Patients capable of providing informed consent

### **Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

110 years

**Sex**

All

**Total final enrolment**

212

**Key exclusion criteria**

1. Patients with a diagnosis of a cancer secondary to a primary cancer
2. Any patients who are acutely ill or receiving end-of-life care
3. Patients with a recurrent cancer

**Date of first enrolment**

28/04/2025

**Date of final enrolment**

05/06/2025

**Locations****Countries of recruitment**

Kenya

**Study participating centre**

**Kenyatta National Hospital**

Hospital Road

Nairobi

Kenya

PO Box 20723-00202

**Sponsor information****Organisation**

University of Birmingham

**ROR**

<https://ror.org/03angcq70>

## **Funder(s)**

**Funder type**

Government

**Funder Name**

National Institute for Health and Care Research

**Alternative Name(s)**

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Data sharing statement to be made available at a later date